Abstract:You have accessJournal of UrologyBenign Prostatic Hyperlasia: Medical and Hormonal Therapy1 Apr 20131383 COMBINATION OF α-ADRENERGIC RECEPTOR BLOCKERS AND 5 α-REDUCTASE INHIBITORS FOR MODERATE TO SEVERE BENIGN PROSTATE HYPERPLASIA (BPH) PATIENTS WITH OR WITHOUT CONCOMITANT HYPERTENSION: RESULTS OF A PROSPECTIVE OBSERVATIONAL REAL-LIFE CLINICAL PRACTICE STUDY USING MULTICENTER REGISTRIES IN CHINA Ying-Hao Sun, Chuan-Liang Xu, Bo Yang, and Tie Zhou Ying-Hao SunYing-Hao Sun Shanghai, China, People's Republic of More articles by this author , Chuan-Liang XuChuan-Liang Xu Shanghai, China, People's Republic of More articles by this author , Bo YangBo Yang Shanghai, China, People's Republic of More articles by this author , and Tie ZhouTie Zhou Shanghai, China, People's Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2737AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Both BPH and hypertension require long term medication therapy. We sought to study the efficacy of combination of α-adrenergic receptor blockers (AB) and 5 α-reductase inhibitors (5ARI) for moderate to severe BPH patients with or without concomitant hypertension by analyzing the data from our 1 year's prospective observational real-life clinical practice study using multicenter registries in China. METHODS The primary outcomes were the medication pattern and efficacy of the combination regimen as reflected by Prostate Volume (PV), maximum urinary flow rate (Qmax) and I-PSS. Serum Prostate-Specific Antigen (PSA) was also determined. RESULTS Among 2786 eligible patients, 68.92% (n=1920) patients were normotensive while 31.08% (n=866) were hypertensive and they were comparable in baseline characteristics except blood pressures (BP). At baseline, all the normotensive and hypertensive patients received AB and 5ARI combination regimen. At 12 months, 2675 patients are available, including 769 hypertensive ones. Qmax improvement was comparable in normotensive and hypertensive patients (P=0.3786). PV significantly declined in normotensive and hypertensive BPH patients from the baseline (P<0.0001 vs. baseline in both; P=0.5989, normotensive vs. hypertensive). I-PSS was improved greater in normotensive than in hypertensive BPH patients (P<0.0001), but both significantly higher than the baseline (P<0.0001). The combination regimen lowered mean systolic and diastolic BP by 7.3±14.05 and 3.1±9.95 mmHg, respectively, in hypertensive BPH patients (P<0.05 vs. baseline in both). CONCLUSIONS The AB and 5ARI combination regimen significantly improves BPH symptoms in both hypertensive and normotensive BPH patients and also has beneficial effect on BP in hypertensive BPH patients. Baseline characteristics of benign prostate hyperplasia patients with or without concomitant hypertension Characteristics All Patients Normotensive Hypertensive⁎ P value Systolic blood pressure (mmHg) 133.7±13.65 128.1±9.71 140.0±14.62 < 0.0001 Diastolic blood pressure (mmHg) 80.6±9.36 77.2±7.48 85.0±9.73 < 0.0001 PSA (ng/mL) 2.9±1.97 2. 9±1.95 2.8±2.01 0.3014 I-PSS 17.5± 5.38 17.5±5.38 17.4±5.36 0.6062 Prostate Volume (mL) 47.8±16.58 47.7±16.98 48.1±15.66 0.5881 Qmax (ml/sec) 11.6±3.55 11.7±3.49 11.5±3.67 0.2830 ⁎ Including patients with the hypertension history, under anti-hypertension treatment or newly diagnosed hypertension. Efficacy of combination treatment with α-adrenergic receptor blockers and 5α-reductase inhibitors for BPH patients with or without concomitant hypertension at 12 months Characteristics Normotensive Hypertensive P value Systolic blood pressure (mmHg) 7.4±9.93 7.3±14.05 0.8607 Diastolic blood pressure (mmHg) 2.7±8.16 3.1±9.95 0.5930 PSA (ng/mL) 0.8±1.66 0.8±2.65 0.8500 I-PSS 6.8±5.45 5.7±4.23 <0.0001 Prostate Volume (mL) 6.2±8.74 6.4±8.06 0.5989 Qmax (ml/sec) 2.4±2.75 2.5±3.34 0.3786 © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e566 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ying-Hao Sun Shanghai, China, People's Republic of More articles by this author Chuan-Liang Xu Shanghai, China, People's Republic of More articles by this author Bo Yang Shanghai, China, People's Republic of More articles by this author Tie Zhou Shanghai, China, People's Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Personalized Therapeutics of &Amp;alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of Α1-Blockers In patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

The efficacy of α1-adrenergic receptor blocker, 5α-reductase inhibitor or combination therapy in benign prostatic hyperplasia

PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY

Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription

Clinical Study of Combination Therapy of Tamsulosin and Solifenacin for Benign Prostatic Hyperplasia with Overactive Bladder

Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

The role of combination medical therapy in benign prostatic hyperplasia

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis

Systematic Review and Meta-Analysis on Phosphodiesterase 5 Inhibitors and Α-Adrenoceptor Antagonists Used Alone or Combined for Treatment of LUTS Due to BPH

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

A Randomized Placebo-Controlled Study: Phellodendron Bawei Tablets Combined with Standard Management Can Improve Storage Symptoms, Sleep Quality, and Medication Compliance in Patients with Benign Prostatic Hyperplasia Compared to Placebo with Standard Management.

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

Comparative efficacy of commercial oral poly-herbal traditional Chinese medicine formulations combined with western medicine in benign prostatic hyperplasia management: a systematic review and network meta-analysis

High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia

Combination Therapy with Curcumin Plus Tamsulosin and Finasteride in the Treatment of Men with Benign Prostatic Hyperplasia: a Single Center, Randomized Control Study

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

Single drug versus combination therapy with terazosin and amlodipine for middle-aged and old male patients with bladder outlet obstruction associated with benign prostatic hyperplasia and their quality of life

Efficacy of combination therapy with 5 alpha-reductase inhibitor and alpha-receptor blocker for the treatment of intravesical prostatic profusion in patients with benign prostatic hyperplasia

Personalized Therapeutics of &Amp;alpha;1-Blockers In&amp;nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia